Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein-Reference-Cited by-同舟云学术

Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein

Published:2022-11-04 Issue:12 Volume:13 Page:1885-1891
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Ohoka Nobumichi¹^ORCID,Suzuki Masanori²,Uchida Takuya³,Tsuji Genichiro⁴^ORCID,Tsukumo Yoshinori¹,Yoshida Masayuki²,Inoue Takao¹,Demizu Yosuke⁴^ORCID,Ohki Hitoshi²,Naito Mikihiko¹⁵^ORCID

Affiliation:

1. Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Kawasaki, Kanagawa 210-9501, Japan

2. Modality Research Laboratories, Biologics Division, Daiichi Sankyo Co., Ltd., Tokyo 140-8710, Japan

3. Medicinal Chemistry Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Tokyo 140-8710, Japan

4. Division of Organic Chemistry, National Institute of Health Sciences, Kawasaki, Kanagawa 210-9501 Japan

5. Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan

Funder

Japan Agency for Medical Research and Development

Princess Takamatsu Cancer Research Fund

Japan Society for the Promotion of Science

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00402

Reference28 articles.

1. Targeting FLT3 mutations in AML: review of current knowledge and evidence

2. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment

3. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia

4. Gilteritinib: potent targeting of FLT3 mutations in AML

5. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives;European Journal of Medicinal Chemistry;2024-11

2. Exploring Degradation of Intrinsically Disordered Protein Yes-Associated Protein Induced by Proteolysis TArgeting Chimeras;Journal of Medicinal Chemistry;2024-08-27

3. Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia;Bioorganic Chemistry;2024-08

4. The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation;Drug Discovery Today;2024-07

5. Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors;Journal of Medicinal Chemistry;2024-04-24